Secukinumab vs. Adalimumab for the Treatment of Psoriatic Arthritis- A Cost Per Responder Analysis at 48 Weeks from a Brazilian Perspective
Oct 1, 2017, 00:00 AM
10.1016/j.jval.2017.08.2979
https://www.valueinhealthjournal.com/article/S1098-3015(17)33313-2/fulltext
Section Title :
Disease-Specific Studies
Section Order :
2723
First Page :
A938
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)33313-2&doi=10.1016/j.jval.2017.08.2979